Well, Botox is AGN’s most profitable product by a wide margin, and the competitive landscape for Botox just got more secure.
Still, I question whether VRX can digest so many acquisitions in a short time without botching the effort. Moreover, I don’t think David Pyott is ready to retire, so I wonder what role Ackman and VRX have in mind for him.
All told, this deal is an underdog to be consummated, IMHO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.